Home / Companies / IGC Pharma, Inc. / 18 Aug 2023
IGC Pharma, Inc.: meeting of 18 Aug 2023
Votes reported on Form N-PX, item by item
23 Form N-PX filers reported votes at the IGC Pharma, Inc. meeting of 18 Aug 2023. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
1 nominee; 16.7% of reported votes for; 3 filers withheld from or voted against at least one nominee.
6 vote records from 4 filers. 3 of the 4 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
26 vote records from 22 filers. 3 of the 21 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
SECTION 14A SAY-ON-PAY VOTESIssuer
Frequency of the say-on-pay vote
one year: 20 filers; three years: 1 filer; two years: 1 filer.
27 vote records from 23 filers. 20 of the 21 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
6 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
7 vote records from 5 filers. 4 of the 5 filers that marked the item either way voted against management.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
6 vote records from 4 filers. 4 of the 4 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Pay-vote frequency | 4. Auditor |
|---|---|---|---|---|
| Vanguard | Abstain or withhold * | For | Split or no vote * | For |
| BlackRock and iShares | For | For | Split or no vote * | For |
| Fidelity | Abstain or withhold * | For | Split or no vote * | For |
| State Street and SPDR | No report | For | Split or no vote * | No report |
| Goldman Sachs | No report | For | Split or no vote * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the IGC Pharma, Inc. meeting?
23 Form N-PX filers reported votes at the meeting of 18 Aug 2023. On say-on-pay, 3 of 21 voted against management (14.3%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by IGC Pharma, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for IGC Pharma, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing IGC Pharma, Inc. with a meeting date within three days of 18 Aug 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.